NCT02314156 - Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

January 31, 2018

Study Completion Date

May 31, 2021

Conditions

BRCA1 Mutation CarrierBRCA2 Mutation CarrierDuctal Breast Carcinoma In SituLobular Breast Carcinoma In SituStage 0 Breast CancerStage IA Breast CancerStage IB Breast CancerStage IIA Breast CancerStage IIB Breast Cancer

Interventions

DRUG

Telapristone Acetate

Given transdermally

OTHER

Placebo

Given PO

DRUG

Telapristone Acetate

Given PO

OTHER

Placebo

Given transdermally

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (3)

10065

Memorial Sloan-Kettering Cancer Center, New York

60611

Northwestern University, Chicago

90048

Cedars-Sinai Medical Center, West Hollywood

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER